Merus (NASDAQ:MRUS) Receives $86.00 Consensus PT from Brokerages

Shares of Merus (NASDAQ:MRUS - Get Free Report) have been given a consensus rating of "Buy" by the sixteen research firms that are covering the stock, Marketbeat reports. Fourteen equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $86.00.

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price objective on shares of Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. BMO Capital Markets set a $110.00 price target on shares of Merus and gave the company an "outperform" rating in a report on Friday, May 23rd. Guggenheim reaffirmed a "buy" rating and set a $109.00 price target on shares of Merus in a report on Friday, March 28th. William Blair reaffirmed an "outperform" rating on shares of Merus in a report on Monday, April 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 price target on shares of Merus in a report on Monday, May 19th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MRUS. GAMMA Investing LLC boosted its stake in Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 603 shares during the last quarter. State of Wyoming bought a new position in shares of Merus in the 4th quarter worth about $48,000. Wells Fargo & Company MN lifted its position in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after buying an additional 300 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Merus in the 4th quarter worth about $60,000. Finally, Avior Wealth Management LLC bought a new position in shares of Merus in the 4th quarter worth about $76,000. 96.14% of the stock is currently owned by institutional investors.

Merus Stock Up 0.6%

Shares of Merus stock traded up $0.32 during trading hours on Tuesday, hitting $55.69. The company's stock had a trading volume of 1,831,794 shares, compared to its average volume of 735,561. Merus has a 1-year low of $33.19 and a 1-year high of $61.28. The business has a fifty day moving average of $43.29 and a 200 day moving average of $43.56. The company has a market capitalization of $3.85 billion, a PE ratio of -14.10 and a beta of 0.94.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.23). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. On average, sell-side analysts anticipate that Merus will post -3.85 earnings per share for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.